• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Resected Colon Cancer Case Features Ultrahigh Mutational Burden and POLE Mutation

by
November 13, 2026
in Cancer, Health
Reading Time: 6 mins read
0
Resected Colon Cancer Case Features Ultrahigh Mutational Burden and POLE Mutation

Resected Colon Cancer Case Features Ultrahigh Mutational Burden and POLE Mutation

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In a clinical report published in Frontiers in Oncology, oncologists from The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine and Affiliated Hospital of Zunyi Medical University evaluated a man in his early forties with familial adenomatous polyposis who underwent surgery for stage IIIB ascending colon adenocarcinoma. Familial adenomatous polyposis is typically caused by a heterozygous pathogenic germline APC variant, conferring substantial lifelong colorectal cancer risk alongside extensive gastrointestinal polyps. Although proofreading-domain alterations in DNA polymerase epsilon, notably POLE p.P286R, drive marked hypermutation and elevated mutational burdens in microsatellite-stable colorectal malignancies, their role in postoperative management remains poorly established. The researchers detailed the patient’s diagnostic workup, paired tumor-blood targeted sequencing, conflicting mismatch repair testing, and subsequent surveillance following subtotal colectomy and five doses of the PD-1 inhibitor sintilimab. The investigators emphasized that this postoperative observation illustrates key molecular assessment challenges but cannot establish adjuvant immunotherapy efficacy or clinical cure.

The patient was admitted in January 2025 reporting a several-year history of loose stools and increased defecation frequency, with no prior family history of hereditary disease identified. Baseline serum assessments performed on January 15, 2025, recorded a carcinoembryonic antigen concentration of 8.51 nanograms per milliliter, a CA72-4 measurement of 12.10 units per milliliter, and a CA19-9 level of 13.10 units per milliliter. Preoperative abdominal computed tomography revealed an ascending colon and hepatic flexure soft-tissue lesion accompanied by regional lymphadenopathy, with small hepatic cysts and benign hepatic perfusion changes but no definitive liver metastasis. Chest computed tomography completed on January 18 demonstrated no evidence of pulmonary metastasis. Biopsies confirmed invasive adenocarcinoma within the ascending colon and low-grade tubular adenomas within the transverse colon, establishing a clinical polyposis syndrome with concurrent colonic malignancy requiring surgical resection.

On January 24, 2025, surgeons executed a laparoscopic subtotal colectomy with loop ileostomy to resect the ascending colon tumor and manage the widespread polyposis. Histopathological assessment of the resected bowel demonstrated a moderately to poorly differentiated adenocarcinoma invading through the muscularis propria into the subserosa of the bowel wall. Regional nodal dissection identified metastatic adenocarcinoma in two of thirty-three harvested pericolonic lymph nodes, while a separate mesenteric-root node showed no malignant cells. The terminal ileum surgical margin was free of tumor invasion, whereas a low-grade tubular adenoma was present at the colonic margin. Gross examination showed hundreds of miliary nodules covering the mucosal surface, which corresponded microscopically to low-grade tubular adenomas. In accordance with the eighth edition of the American Joint Committee on Cancer staging system, the tumor was classified as pathological stage pT3N1b, clinically M0, stage IIIB disease, confirming locally advanced colon carcinoma with regional lymph node metastasis.

Subsequent diagnostic workup generated marked discrepancies between initial immunohistochemical testing and subsequent molecular profiling. Initial mismatch repair immunohistochemistry performed on an automated platform using commercial reagents reported pan-loss across all four proteins, MLH1, MSH2, MSH6, and PMS2, which suggested mismatch repair deficiency. Because responses to PD-1 blockade are substantially more frequent in mismatch repair-deficient than mismatch repair-proficient colorectal cancer, this preliminary finding guided initial treatment while sequencing was pending. However, following targeted next-generation sequencing that classified the tumor as microsatellite stable, the pathology service recut the tissue and repeated the panel, interpreting the second staining run as proficient mismatch repair. The study authors reported that original block identifiers, antibody clone specifications, case-specific cold-ischemia and formalin-fixation times, and run-level internal controls could not be retrieved retrospectively. As a result, technical explanations for the initial pan-loss could not be verified, leaving unresolved whether the conflicting result arose from laboratory preanalytical artifacts or biological specimen heterogeneity.

Comprehensive genomic characterization of the primary adenocarcinoma and matched peripheral blood was conducted using a 769-gene Baishibo targeted sequencing panel encompassing an effective exonic denominator of 1.027 megabases. Tumor cellularity was histologically estimated at 60 to 70 percent. Sequencing revealed an ultrahigh tumor mutational burden of 333.57 mutations per megabase, which placed the tumor at the 99.77th percentile of the laboratory’s colorectal cancer reference database. Mutational burden was calculated by dividing qualifying nonsynonymous somatic single-nucleotide variants and small indels by the exonic footprint, after filtering out germline variants and designated driver alterations. Targeted evaluation of 519 microsatellite loci classified the neoplasm as microsatellite stable, though algorithmic decision cutoffs were unavailable and no PCR-based testing was conducted. Immunohistochemical evaluation of PD-L1 expression demonstrated a tumor proportion score below one percent and a combined positive score of 3, while Ki-67 reached approximately 80 percent and p53 analysis remained uninterpretable.

Targeted sequencing identified a somatic POLE proofreading-domain mutation, c.857C>G (p.P286R), at a variant allele fraction of 19.75 percent in tumor tissue, which was absent from circulating blood cells. Concurrently, paired germline testing identified a pathogenic nonsense mutation in APC, c.694C>T (p.R232*), present at 47.16 percent in blood and 43.43 percent in tumor tissue. Because parental genetic testing and formal cascade screening records were unavailable, the origin could not be definitively classified as inherited or de novo. The tumor also harbored three additional truncating somatic APC variants: p.R302* at 1.77 percent, p.R876* at 17.56 percent, and p.E1257* at 12.50 percent, alongside MLH1 p.R659* at 14.20 percent and MSH6 p.R1334Q at 8.41 percent. No canonical activating mutations in KRAS or NRAS exons 2 through 4, BRAF V600E, or TP53 alterations were identified within the tested panel boundaries. Without allele-specific phasing, the initiating APC second-hit inactivation mechanism remained unresolved.

Following surgical intervention, longitudinal tracking of serum biomarkers demonstrated marked postoperative clearance prior to any systemic pharmacological treatment. Between baseline measurements on January 15 and postoperative testing on February 13, 2025, serum carcinoembryonic antigen concentrations dropped from 8.51 to 3.39 nanograms per milliliter, normalizing within standard reference ranges before systemic drug delivery. Concurrently, serum CA72-4 declined from 12.10 to 7.60 units per milliliter over the same postoperative interval, approaching the upper normal reference limit of 6.9 units per milliliter. The patient and his family declined conventional adjuvant cytotoxic chemotherapy for personal reasons. On February 14, 2025, clinicians administered an initial 200-milligram dose of the PD-1 inhibitor sintilimab, guided by the initial immunohistochemical pan-loss interpretation while genomic testing was pending. After the genomic report was issued on March 7 confirming microsatellite stability, ultrahigh tumor mutational burden, and POLE p.P286R, multidisciplinary review elected to continue checkpoint inhibition.

In total, the patient received five intravenous doses of sintilimab at 200 milligrams per cycle on February 14, March 13, April 3, April 24, and May 15, 2025. Although treatments were planned at three-week intervals, the initial cycle gap spanned 27 days, and specific reasons for this delay or for discontinuing treatment after five doses could not be retrieved retrospectively. No clinically apparent immune-related adverse events were reported, though formal grading using standard toxicity criteria was not documented. Follow-up serum testing on June 17, 2025, demonstrated that CA72-4 had normalized to 5.43 units per milliliter, while carcinoembryonic antigen remained normal at 2.62 nanograms per milliliter. Subsequent surveillance colonoscopy in July 2025 identified residual colonic polyps, with biopsies confirming benign adenomatous tissue without invasive carcinoma. Multi-modality radiological surveillance through September 14, 2026—comprising abdominal computed tomography and chest radiography approximately twenty months after surgery—revealed no evidence of local tumor recurrence or distant metastatic progression.

The case report contextualized these findings by examining previously published literature on POLE-mutant colorectal malignancies and established adjuvant clinical trial paradigms. Earlier publications, including reports by Gong and colleagues on POLE p.V411L, Xiang and colleagues on POLE p.P286R in familial polyposis, and Zimmerman and colleagues on POLE p.A456P, all evaluated patients who had measurable metastatic, advanced, or unresectable disease prior to immune checkpoint therapy. In those metastatic settings, radiological evaluations documented objective tumor reductions or partial responses following treatment. By contrast, the present patient had no measurable radiographic disease at immunotherapy initiation following macroscopic surgical resection. Furthermore, clinical trials in resected colon cancer do not support five cycles of single-agent immunotherapy. The IDEA collaboration evaluated three versus six months of oxaliplatin-based chemotherapy in stage III disease, whereas the ATOMIC trial demonstrated disease-free survival improvements with one year of atezolizumab combined with chemotherapy specifically in mismatch repair-deficient stage III cancers, a trial population distinct from this microsatellite-stable tumor.

The study authors detailed multiple clinical and methodological limitations that preclude causal attribution of the patient’s recurrence-free status to sintilimab. Because complete surgical resection removed all measurable tumor before systemic therapy, subsequent disease stability cannot be categorized as an objective antitumor response under established oncological criteria. In addition, localized POLE-mutated colorectal cancers may have a favorable prognosis, and approximately twenty months of follow-up is insufficient to establish durable cure. The investigators also emphasized key technical constraints, including absent circulating tumor DNA monitoring, lack of whole-exome sequencing, unperformed mutational signature SBS10 analysis, unverified APC second-hit allelic phasing, unsequenced residual polyps, and incomplete documentation of immunohistochemical assay controls. Consequently, this observation provides valuable biological hypotheses regarding hypermutated colorectal neoplasms but cannot establish the efficacy of adjuvant PD-1 monotherapy.

Subject of Research: Molecular characterization and clinical course of familial adenomatous polyposis-associated colon cancer with POLE mutation

Article Title: Familial adenomatous polyposis-associated stage IIIB colon cancer with ultrahigh tumor mutational burden and POLE p.P286R mutation: a case report

Article References: Cai, H., Chen, H., Wu, W., & Tang, D. (2026). Familial adenomatous polyposis-associated stage IIIB colon cancer with ultrahigh tumor mutational burden and POLE p.P286R mutation: a case report. Frontiers in Oncology, 16, Article 1912024. https://doi.org/10.3389/fonc.2026.1912024

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1912024

Keywords: Familial Adenomatous Polyposis, POLE p.P286R, Tumor Mutational Burden, Stage IIIB Colon Cancer, Sintilimab, Microsatellite Stability, Mismatch Repair Immunohistochemistry, APC Germline Mutation, Ascending Colon Adenocarcinoma, Subtotal Colectomy, DNA Polymerase Epsilon, Immune Checkpoint Blockade, Carcinoembryonic Antigen, Cancer Surveillance, Targeted Gene Panel Sequencing, Colorectal Polyposis, Adjuvant Immunotherapy

News Source: Nathaniel Bowman. (November 13, 2026). Resected Colon Cancer Case Features Ultrahigh Mutational Burden and POLE Mutation. Scienmag.

Tags: adjuvant immunotherapyAPC Germline MutationAscending Colon Adenocarcinomacancer surveillanceCarcinoembryonic AntigenColorectal PolyposisDNA Polymerase Epsilonfamilial adenomatous polyposisimmune checkpoint blockademicrosatellite stabilityMismatch Repair ImmunohistochemistryPOLE p.P286RsintilimabStage IIIB Colon Cancersubtotal colectomyTargeted Gene Panel Sequencingtumor mutational burden
Share12Tweet7Share2ShareShareShare1

Related Posts

Bioinformatic Analysis Highlights Candidate Genes Linked to Nasopharyngeal Carcinoma Drug Resistance

Bioinformatic Analysis Highlights Candidate Genes Linked to Nasopharyngeal Carcinoma Drug Resistance

November 20, 2026
Cucurbitacin B and Resveratrol Combination Demonstrates Synergistic Antitumor Activity in Breast Cancers

Cucurbitacin B and Resveratrol Combination Demonstrates Synergistic Antitumor Activity in Breast Cancers

November 20, 2026

India Launches National HPV Vaccination Programme

November 20, 2026

Inpatient Mental Health Units Face Severe Staff Shortages and Safety Crises

November 20, 2026

POPULAR NEWS

  • One Distal Screw Matches Two in Humeral Nailing Functional Outcomes

    One Distal Screw Matches Two in Humeral Nailing Functional Outcomes

    29 shares
    Share 12 Tweet 7
  • Adipose CD248 Rises in Obesity and Responds Directly to Glucocorticoids

    29 shares
    Share 12 Tweet 7
  • Predictable Human Food Prompts Alpine Choughs to Undertake Daily Routine Altitudinal Flights

    29 shares
    Share 12 Tweet 7
  • Alien Plant Spatial Metrics Vary in Reliability Under Simulated Incomplete Sampling

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Reinforcement Learning Optimizes Dynamic Admission Control for Preemptible Cloud Services

Heterogeneous Graph Learning Traces Student Knowledge Across Graded Cognitive Levels

AK Iteration Improves Fixed Point Approximations and Solves Volterra Integral Equations

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.